Socio-Demographic and Clinical Determinants of Psychiatric Co-Morbidity in Persons with Essential Hypertension in Port Harcourt, Nigeria
American Journal of Psychiatry and Neuroscience
Volume 3, Issue 6, November 2015, Pages: 142-153
Received: Dec. 24, 2015; Accepted: Jan. 13, 2016; Published: Jan. 29, 2016
Views 2868      Downloads 53
Authors
Nkporbu Aborlo Kennedy, Department of Neuropsychiatry, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
Eze George, Federal Neuropsychiatric Hospital Uselu, Benin City, Nigeria
Stanley Princewill Chukwuemeka, Department of Neuropsychiatry, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
Article Tools
Follow on us
Abstract
The prevalence of essential hypertension has continued to increase worldwide and its consequences have remained a growing concern. A number of socio-demorgrahic and clinical variables may however serve as key determinants of the extent to which it is associated with psychiatric comorbidity. The aim of this study, therefore, was to determine the socio-demorgraphic and clinical factors that may influence the level of psychiatric co-morbidity associated with persons with essential hypertension attending the general out-patient clinic of the university of Port Harcourt Teaching Hospital (UPTH). Following ethical approval from the appropriate committee of the hospital and informed consent from the participants, 360 subjects making up the study group were recruited based on the study’s inclusion and exclusion criteria. A pilot study was carried out. Subjects were further administered with the study’s instruments including the socio-demographic/clinical questionnaire, GHQ-12, and WHO Composite International Diagnostic Interview (WHO CIDI). The socio-demographic/clinical questionnaire and GHQ-12 were self-administered while the WHO CIDI was based on interview by the researcher. The data were analyzed using the SPSS version 16 statistical package. Confidence interval was set at 95% while P- value of less than 0.05 was considered statistically significant. The study found a prevalence of psychiatric co-morbidity of 64.4% among the hypertensives. Among the study group, there was no significant relationship between the presence of psychiatric co-morbidity and age class (p=0.350), gender (p=0.22), level of education (p=043), and occupation (p=0.82). Persons who were married were significantly more likely to have a psychiatric co-morbidity (p=0.001). Also, those who reacted with either ‘very sad’ or a ‘wish to die’ when they were informed of the diagnosis of the medical conditions (p=0.001), low income (p=0.001) and severity of B. P (p=0.001) were more likely to have psychiatric comorbidity (p=0.001). There was also no significant relationships between age of onset of illness (p=0.60), duration of illness (p=0.73), duration of treatment (p=0.82), and self stigma (p=0.15). The findings of this study support the impression that essential hypertension is a chronic debilitating illness, associated with psychiatric co-morbidity, that are largely significantly influenced by a number of socio-demorgraphic and clinical factors. The results support the call that the management of patients with essential hypertension should include attention to not only their mental health status, but also the psychosocial and other clinical factors they may present with in order to enhance the quality of care.
Keywords
Socio-Demorgrphic/Clinical, Determinants, Essential Hypertension, Psychiatric Co-morbidity, UPTH
To cite this article
Nkporbu Aborlo Kennedy, Eze George, Stanley Princewill Chukwuemeka, Socio-Demographic and Clinical Determinants of Psychiatric Co-Morbidity in Persons with Essential Hypertension in Port Harcourt, Nigeria, American Journal of Psychiatry and Neuroscience. Vol. 3, No. 6, 2015, pp. 142-153. doi: 10.11648/j.ajpn.20150306.16
Copyright
Copyright © 2015 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Oviasu VO. The Pattern and Prevalence of Heart Disease in Benin, Nigeria. Nig. Med. J. 1989; 8: 83-85.
[2]
WokomaFS, Alasia DD. Blood pressure pattern in Barako: a rural community in Rivers State, Nigeria. The Nigeria Journal, 2011; 11: 813.
[3]
AkpaMR, Alasia DD, Emmen-Chioma PC. An appraisal of hospital based blood pressure control in Port Harcourt, Nigeria. The Nigeria Health Journal.2008; 8: 27-30.
[4]
UnachukwuCN, Agomoh DI, Alasia DD. Pattern of non-communicable diseases among medical admissions in Port Harcourt, Nig. Nig. Journal of Clinical Practice.2008; 11 (1): 14-17.
[5]
Adefuye BO, Adefuye PO, Oladepo TO, Familoni OB, Olurunga TO. Prevelence of hypertension and other cardiovascular risk factors in an African Urban, sub-urban religious community. Nigerian Medical Practitioner 2009; 55 (1-2): 4-8.
[6]
Cooper R, Rotimi C, Ataman S, McGee D, Osotimehin B, Kadiri S et al. The prevalence of hypertension in seven populations of west Africanorigin. Am Public Health 1997; 87 (2): 160-8.
[7]
Kearney PM, Whelton M, Renoids K, Muntner, P WhentonKP. Global burden of hypertension: analysis of worldwide data Lancet 2005; 365: 217-23.
[8]
Murray CJ, Lopez AD. Mortality by cause for eight regions of the world. Global burden of disease. Lancett, 1997; 349: 1269-1276.
[9]
Ogbagbon EK, Okesina AB, Biliaminu SA. Prevalence of hypertension and associated variables in paid workers in llorin, Nigeria. Niger J. Clin. Pract. 2008; 11 (4): 342-346.
[10]
Lawes CM, Vander Hoorn S, Law MR Eliot P, McMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. part II: estimate of attributable burden J. hypertens 2006; 24: 423-430.
[11]
Cappuccio FP, Cook DG, Atkinson RW and Strazzullo P. Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London. Heart1997; 78 (6): 555-63.
[12]
Cooper R, Rotimi C, Ataman S, McGee D, Osotimehin B, Kadiri S, et al. The prevalence of hypertension in seven populations of west Africanorigin. Am Public Health.1997; 87 (2): 160-8.
[13]
Adedoyin RA, Mbada CE, Balogun MO, Martins T, Adabayo RA, Akintomide A. Prevalence and pattern of hypertension in a semi-urban community in Nigeria Eur. J. Cardiovasco prev. Rehab., 2008; 15(6): 683.687.
[14]
Cappuccio FP, Micah FB, Emmeth L, Kerry SM. Prevalence, detection, management and control of hypertension in Ashanti, West Africa. Hypertens, 2004; 43: 10-17.
[15]
Cappuccio FP, Cook DG, Atkinson RW, Stuzzullo P. Prevalence, detection, management of cardiovascular risk factors in different ethinic groups in South Africa. J Health, 1997; 78: 555-563.
[16]
Lawoyin TO, Azuzu MC, Kaufman J, Rotimi C, Oweaje E, Johnson L, Cooper R. Prevalence of cardiovascular risk factors in an African, urban inner city community. westAfr. Med 2002; 21: 208-211.
[17]
Chamontin B, Poggi L, Lang T, Menard J, Chevalier H, GalloisH, Cremier O. Prevalence, treatment and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 1998; 11: 759–62.
[18]
Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, HenseHW, Joffres NM, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Steg-mayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. Hypertension, prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 89: 2363–9.
[19]
Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206.
[20]
WHO (2002). The world Health Report: reducing risks, promoting healthy life. Geneva: World Health Organization, (Cited 2008 March). Available from: URL en. Pdf.
[21]
ArodimeEB, IkeSO, NwokedinkeSC. Case fatality among hypertensive-related admission in Enugu, Nig. Nig Journal of Clinical Practice, 2009: 12 (2): 153-156.
[22]
Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life - a population study. Diabetes Care 2004; 27: 1066–70.
[23]
Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and dis-ease progression. Biol Psychiatry 2003; 54: 269–82.
[24]
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, IzzoJLJr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, RoccellaEJ. Seventhresport of the Joint National committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206-1252.
[25]
Norbert S, Wolfganf T, Johannrs K. Mental Disorders and Hypertension: Factors Associated With Awareness and treatment of Hypertension in the General population of Germany. psychosomatic medicine. 2006; 68: 246-252.
[26]
Erhun WO, Olayiwola, G, AgbaniEO, and OmotosoNS. Prevalence of Hypertension in a University Community in South Western Nigeria. African journal of Biomedical Research Ibadan Biomedical Communication Group.2005; Vol. 8: 15-19.
[27]
Gwatkin D, Guillot M, Heuveline P. The burden of disease among the global poor. Lancet, 2000; 354: 586-589.
[28]
Wenzel U, Roben T, Schwietzer G, Stahl RAK. The treatment of arterial hypertension: a questionnaire survey among doctors in general practice. Deut Med Wochenschr 2001; 126: 1454–9.
[29]
Hartley RM, Velez R, Morris RW, Dsouza MF, Heller RF. Confirming the diagnosis of mild hypertension. BMJ1983; 286: 287–9.
[30]
Gupta K. Undertreatment of hypertension: a dozen reasons. Arch Intern Med 2002; 162: 2246–7.
[31]
Oliveria SA, Lapuerta P, McCarthy BD, L’ItalienGJ, BerlowitzDR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162: 413–20.
[32]
Hyman DJ, PavlikVN. Poor hypertension control: let’s stop blaming the patients. Cleve Clin J Med 2002: 69(10): 793-9.
[33]
Hyman DJ, PavlikVN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479–86.
[34]
DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol2004; 23: 207–18.
[35]
DiMatteoMR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment—meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–7.
[36]
Schmitz N, Kruse J. The relationship between mental disorders and medical service utilization in a representative community sample. Soc Psychiatry PsychiatrEpidemiol 2002; 37: 380–6.
[37]
Anderson RB, Testa MA. Symptom Distress Checklists as a Component of Quality-of-Life Measurement Comparing Prompted Reports by Patient and Physician with Concurrent Adverse Event Reports Via the Physician. Drug inf. J.1994; 28: 89-14.
[38]
Testa MA, Simonson DC. Measuring Quality of Life in Hypertensive Patients with Diabetes. Postgrad Med. J. 1988; 64: Suppl 3: 50-8.
[39]
Testa MA, Hollenberg Anderson RA, Williams GH. Assessment of Quality of Life by Patient and Spouse during Antihypertensive Therapy with Atenolol and Nifedipine Gastrointestinal Therapeutic System Am. J. Hypertens.1991; 4: 363-73.
[40]
Olusina AK, OhaeriJU, Subjective quality of life of recently discharged Nigerian Psychiatric patients. Soc Psychiatry Epidemiol 2003; 38 (12): 707-4.
[41]
Concepts of Health-Related Quality of Life. In: Patrick D. L, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press, 1993; 76-112.
[42]
Wenzel U, Roben T, Schwietzer G, Stahl RAK. The treatment of arterial hypertension: a questionnaire survey among doctors in general practice. Deut Med Wochenschr 2001; 126: 1454–9.
[43]
CroogSH, Levine S, Tests MA, et al. The Effects of Antihypertensive Therapy on the Quality of Life. N Engl. J Med 1986; 314: 157-64.
[44]
TestaMA. Interpreting Quality-of-Life Clinical Trial: Data for use in the Clinical Practice of Antihypertensive Therapy. J Hypertens Suppl, 1987; 5: S9-S13.
[45]
Ii W, Liu L, Purnte JG, Li Y, Jiang X, Jin S, Ma. H, Kong L, Ma L, He X, Ma S, Chen C. Hypertension and Health related quality of life: An epidemiological study in Patients attending hospital clinic in China, Journal of Hypertension.2005; 23(9): 1667-1676.
[46]
Rice D, Kelman S, Miller L. The economic burden of mental illness. Hosp Community Psychiatry.1992; 43: 1227-32.
[47]
DuPont R, Rice D, MiIler L, Shiraki S, Rowland C, Hanwood H. Economic costs of anxiety. J anxiety. 1996; 2. 167-72.
[48]
French M, Mauskopf J, League J, Roland E. Estimating the dollar value of health outcomes from drug abuse Interventions. Med Care.1996; 34: 890-910.
[49]
BrigantiEM, Shaw JE, ChadbanSJ, Zimmet PZ, Welborn TA, McNeil JJ, Atkins RC. Untreated hypertension among Australian adults: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study. Med J Aust 2003; 179: 135–9.
[50]
WokomaFS, Alasia DD. Blood pressure pattern in Barako: a rural community in Rivers State, Nigeria. The Nigeria Journal, 2011; 11: 813.
[51]
AkpaMR, Alasia DD, Emmen-Chioma PC. An appraisal of hospital based blood pressure control in Port Harcourt, Nigeria. The Nigeria Health Journal.2008; 8: 27-30.
[52]
UnachukwuCN, Agomoh DI, Alasia DD. Pattern of non-communicable diseases among medical admissions in Port Harcourt, Nig. Nig. Journal of Clinical Practice.2008; 11 (1): 14-17.
[53]
Adefuye BO, Adefuye PO, Oladepo TO, Familoni OB, Olurunga TO. Prevalence of hypertension and other cardiovascular risk factors in an African Urban, sub-urban religious community. Nigerian Medical Practitioner 2009; 55 (1-2): 4-8.
[54]
Cooper R, Rotimi C, Ataman S, McGee D, Osotimehin B, Kadiri S et al. The prevalence of hypertension in seven populations of west Africanorigin. Am Public Health 1997; 87 (2): 160-8.
[55]
Corvol P, Persu A, Gimenez-Roqueplo AP, Jeunemaitre X. “Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel”. Hypertension 1999; 33 (6): 1324—3.
[56]
Feinleib M, Garrison RJ, Fabsi. tz R, et al. “The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results”. American Journal of Epidmiolo 1977; 106 (4): 284-5.
[57]
Biron P, Mongeau JG, Bertrand D. “Familial aggregation of blood pressure in 558 adopted children”. Canadian Medical Association Journal 1976; 115 (8): 773-4.
[58]
Lifton RP, Gharavi AG, Geller DS. “Molecular mechanisms of human hypertension”. 2001. 104(4): 545-56.
[59]
Wilson FH, Disse-Nieodme S, Choate KA, et al. “Human hypertension caused by mutations in WNKkinases”. Science2001; 293 (5532): 1107-l2.
[60]
Pickering 1G. Devereux RB, James GD, et al. Environmental influences on blood pressure and the role of job strain. J hypertens Suppl. 1999; 341: 120-4.
[61]
Svensson J. Theorell, T. Life events and elevated Blood pressure in young men J. Psychosom. Res. 1983; 27: 445-456.
[62]
Svensson J. and Thorell T. Life events and elevated Blood pressure in young. J. Psychosom. Res. 1983; 27: 445-56.
[63]
Fauvel JP, Quelin P, Ducher M, Rakotomalala H, Laville M. Perceived job stress but not individual cardiovascular reactivity to stress is related to higher blood pressure at work. Hypertension 2001; 38(1): 7’l-5.
[64]
Gwatkin D, Guillot M, Heuveline P. The burden of disease among the global poor. Lancet, 2000; 354: 586-589.
[65]
Rutledge T, Hogan BE. A quantitative review of prospective evidence linking psychological factors with hypertension development. Psychosom Med 1999; 64(5): 758-66.
[66]
Jonas BS, Franks P, Ingram DD. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Family Med 1997; 6: 43-9.
[67]
Frasure-Smith N, Lesperance F. Reflections on depression as a cardiacriskfactor. Psychosom Med 2005; 67: S19-25.
[68]
Jonas ES, Franks P, Ingram DO. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. ArchFainMcd.1997; 6: 43-49.
[69]
MarkovitzJH, Matthews KA, Kannel WB, Cobb JL, O’AgostinoRB. Psychological predictors of hypertension in the Frarningham Study. JAMA.1993; 270: 2439-2443.
[70]
Jonas BS. LandoJF. Negative affect as a prospective risk factor for hypertension. Psychosom. Med. 2000; 62: 188-196.
[71]
CotlingtonEM, Brook BM, House IS, Hawthorne VM. Psychosocial factors and blood pressure in the Michigan Statewide Blood Pressure Survey. Am. JEpide. 1985; 121: 515-529.
[72]
OgbagbonEK, Okesina AB, Biliaminu SA. Prevalence of hypertension and associated variables in paid workers in llorin, Nigeria. Niger J. Clin. Pract., 2008; 11 (4): 342-346.
[73]
Oviasu VO. High blood pressure: A silent mysterious killer, a primary preventive approach. Inaugural Lecture. AmbikPress, Benin City 1988; 89.
[74]
Lown B, De Silva RA., Reich P., Murawsk BJ. Psychological factors in sudden cardiac death. Am. J. Psychiat. 1980; 137: 1325-1335.
[75]
Kearney PM, Whelton M, Renoids K, Muntner, P WhentonKP. Global burden of hypertension: analysis of worldwide data Lancet 2005; 365: 217-23
[76]
Nyklicek I, VingerhoetsJJ, Van Heck GL. Hypertension and objective and self- reported stressor exposure: a review. Psychosunr Res. 1996; 40: 585-601.
[77]
Carroll D, Phillips AC, Gale CR, Batty GD. Generalized anxiety and major depressive disorders, their comorbidity and hypertension in middle-aged men. Psychosom Med. 2010; 72: 16-19.
[78]
Landsbergis PA, Sctnrmll FL, Warren K, Pickering IC, Schwartz 28. Association between ambulatory blood pressure and alternative formulations of job strain. Stand Work Environ Health.1994; 20: 349-363.
[79]
Roberts RE, Kaplan GA, CamachaTO. Psychological distress and mortality: evidence from the Alameda County Study. SocSc) Mad. 1990; 31: 527-530.
[80]
Testa MA, Anderson RB, NackleyJF, HollenbergNK. Quality of Life and Antihypertensive Therapy in Men: a Comparison of Captopril with Enalapril, N. Engl. J. Med. 1993; 328: 907-13.
[81]
Ohene S. Psychiatric Morbidity among Patients with Essential Hypertension Attending Out-Patient Clinics in University of Benin Teaching Hospital. Dissert. WACP. 2003.
[82]
Somers VK, Anderson EA, Mark AL. “Sympathetic neural mechanisms in human hypertension”. Current Opinion in Nephrology and Hypertension 1993; 2 (1): 96-105.
[83]
Takahashi H. “[Sympathetic hyperactivity in hypertension]” (in Japanese). Nippon Rinsho. Japanese Journal of Clinical Medicine June 2008; 66 (8): 1495—502.
[84]
Esler M). “The sympathetic system and hypertension”. American Journal of Hypertension13 (6 Pt 2): 99S—105.
[85]
Mark AL. “The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure”. Journal of Hypertension. Sipplernent: Official Journal of the International Society of hypertension 1996; 14(5): S 159—65.
[86]
JeeSH, He J, WheltonPK, etal. The Effect of Chronic Coffee Drinking on Blood Pressure: A Meta-analysis of Controlled Clinical trials. Hypertension 1999; 33: 647-652.
[87]
Lane JD, Pieper CF, Phillips-Bute BG, Bryant JE, kuhnCM. Caffieine affects cardiovascular and neuroendocrine activation at work and home. Psychosom Med 2002; 64(4): 595. 603.
[88]
Mathews JD. Alcohol use, hypertension and coronary heart disease. ClinSciMol Med 1976; 3: 66 IS663S.
[89]
Mena-Martin FJ, Martin- EscuderoJC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. J Hypertens. 2003; 21: 1283-1289.
[90]
Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000; 15: 319–28.
[91]
Anderson RB, Testa MA. Symptom Distress Checklists as a Component of Quality-of-Life Measurement Comparing Prompted Reports by Patient and Physician with Concurrent Adverse Event Reports Via the Physician. Drug inf. J. 1994; 28: 89-14.
[92]
Testa MA, Simonson DC. Measuring Quality of Life in Hypertensive Patients with Diabetes. Postgrad Med. J. 1988; 64: Suppl 3: 50-8.
[93]
LenderkingWR, Gelber RD, Cotton DL, et al. Evaluation of the Quality of Life Associated with Zidovudine Treatment in Asymptomatic Human Immunodeficiency Virus Infection. N Engl. J. Med. 1994; 330: 738-43.
[94]
Olusina AK, OhaeriJU, Subjective quality of life of recently discharged Nigerian Psychiatric patients. Soc Psychiatry Epidemiol 2003; 38 (12): 707-4.
[95]
Concepts of Health-Related Quality of Life. In: Patrick D. L, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press, 1993; 76-112.
[96]
Testa MA, LenderkingWR. Interpreting pharmacoeconomic and quality-of–life clinical trial data for use in therapeutics. Pharmacoeonomics. 1992; 2: 107-17.
[97]
Wells K, Golding J, Burman M. Psychiatric disorder In a sample of the general population with and without chronic medical conditions. Am J Psychiatry. 1988; 145: 976-81.
[98]
Evans D, Charney D. Mood disorders and medical illness a major public health problem. Blot Psychiatry. 2003; 64: 177-80.
[99]
Guidelines Subcommittee. World Health Organization — International Society of Hypertension Guideline for the management of hypertension. JHypertens 1999; 17: 151-83.
[100]
Lisk DR, McEwen EK. The significance and trend of hypertension related deaths in urban Sierra Leonean Africans. J Hum Hypertens. 1996; 10: 215-218. Medline.
[101]
Dressler W. W. Social and Cultural Influences in Cardiovascular Disease: A Review Transcultural Psychiatric Research Review 1984; 21: 1.
[102]
Oviasu VO. A study of arterial blood pressure and hypertension in a rural Nigerian community. Afr. J. 1.
[103]
De Bruyn T. Women and Aids in Developing Countries. Soc. Sci. Med. 1992; 34: 249-62.
[104]
Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens. 1997 Apr; 11(4): 213–220.
[105]
Byrne D. G. Personality, life events and Cardiovascular Diseases. Invited Review in J. of Psychosom Res 1987; 31, 6: 661-671.
[106]
Spiro A, Aldwiri CM, Ward KB, Mroczek DK. Personality and the incidence of hypertension among older men: longitudinal findings from the Normative Aging Study. Health Psycho! 1995; 14: 563-569.
[107]
Brock S, Witte S, Brust J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res, 2008: 13243-8.
[108]
Saddocks BI, Saddocks V. Comprehensive Textbook of Psychiatry. 2005; Vol. 1 pg 426-48.
[109]
Rostrup M, Kjeldsen SE, EideIK. Awareness of hypertension increases blood pressure and sympathetic responses to cold pressor test. Am J Hypertens. 1990; 3: 912-917.
[110]
OparilS, Zaman MA, Calhoun DA. “Pathogenesis of hypertension”. Ann. Intern. Med. 2003; 139 (9): 761_76.
[111]
Kidson MA. Personality and Hypertension J. Psychosom. Res. 1973; 17: 35-41.
[112]
Cochrane R. Hostility and neuroticism J. Psychosom Res. 1973; 21: 58-62.
[113]
NkporbuA. K, Ugbomah L, Stanley P. C. Pattern and Prevalence of Psychiatric Consultations in Other Non-Psychiatric Facilities in the University of Port Harcourt Teaching Hospital: A 5-YEAR REVIEW. The Nigerian Health Journal.2014; 14; 1, 13-20.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186